Adage Capital Partners Portfolio holdings
AUM
$59.3B
1-Year Return
26.26%
This Quarter Return
+1.1%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$50.8B
AUM Growth
-$294M
(-0.58%)
Cap. Flow
-$386M
Cap. Flow
% of AUM
-0.76%
Top 10 Holdings %
Top 10 Hldgs %
22.21%
Holding
1,138
New
128
Increased
273
Reduced
442
Closed
122
Top Buys
| 1 |
Pfizer
PFE
|
+$248M |
| 2 |
Textron
TXT
|
+$204M |
| 3 |
AstraZeneca
AZN
|
+$169M |
| 4 |
Exxon Mobil
XOM
|
+$128M |
| 5 |
Moderna
MRNA
|
+$126M |
Top Sells
| 1 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
+$962M |
| 2 |
Devon Energy
DVN
|
+$252M |
| 3 |
WORK
Slack Technologies, Inc.
WORK
|
+$204M |
| 4 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$170M |
| 5 |
Carrier Global
CARR
|
+$149M |
Sector Composition
| 1 | Technology | 22.31% |
| 2 | Healthcare | 15.98% |
| 3 | Financials | 14.49% |
| 4 | Consumer Discretionary | 11.52% |
| 5 | Communication Services | 8.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQOS
876
DELISTED
EQONEX LIMITED Ordinary Shares
EQOS
| $2.66M | 0.01% |
819,875
+113,991
| +16% | +$369K |
|
877
Standard BioTools
LAB
$489M
| $2.64M | 0.01% |
+400,000
| New | +$2.64M |
|
878
Integral Ad Science
IAS
$1.42B
| $2.63M | 0.01% |
127,668
-572,332
| -82% | -$11.8M |
|
|
CFRX
879
DELISTED
ContraFect Corporation
CFRX
| $2.63M | 0.01% |
8,125
| – | – |
|
880
Phathom Pharmaceuticals
PHAT
$914M
| $2.62M | 0.01% |
81,600
| – | – |
|
881
Arcus Biosciences
RCUS
$1.2B
| $2.62M | 0.01% |
75,000
| – | – |
|
882
Delcath Systems
DCTH
$406M
| $2.61M | 0.01% |
250,000
| – | – |
|
|
ITOS
883
DELISTED
iTeos Therapeutics
ITOS
| $2.57M | 0.01% |
95,000
+38,107
| +67% | +$1.03M |
|
884
Eledon Pharmaceuticals
ELDN
$160M
| $2.53M | 0.01% |
409,759
-443,449
| -52% | -$2.74M |
|
|
SEI
885
Solaris Energy Infrastructure, Inc.
SEI
$1.11B
| $2.52M | 0.01% |
302,430
-15,000
| -5% | -$125K |
|
|
BLU
886
DELISTED
BELLUS Health Inc.
BLU
| $2.46M | ﹤0.01% |
400,000
-1,000,000
| -71% | -$6.14M |
|
887
Design Therapeutics
DSGN
$378M
| $2.42M | ﹤0.01% |
165,000
+119,888
| +266% | +$1.76M |
|
|
MREO
888
Mereo BioPharma
MREO
$290M
| $2.42M | ﹤0.01% |
+1,000,000
| New | +$2.42M |
|
889
CS Disco
LAW
$350M
| $2.4M | ﹤0.01% |
+50,000
| New | +$2.4M |
|
890
T Rowe Price
TROW
$23.5B
| $2.26M | ﹤0.01% |
11,504
-19,500
| -63% | -$3.84M |
|
891
Evercore
EVR
$12.6B
| $2.19M | ﹤0.01% |
16,363
| – | – |
|
892
Day One Biopharmaceuticals
DAWN
$759M
| $2.14M | ﹤0.01% |
+90,000
| New | +$2.14M |
|
893
Novavax
NVAX
$1.29B
| $2.07M | ﹤0.01% |
+10,000
| New | +$2.07M |
|
894
Larimar Therapeutics
LRMR
$331M
| $2.04M | ﹤0.01% |
176,680
+100,000
| +130% | +$1.15M |
|
895
Wave Life Sciences
WVE
$1.19B
| $1.96M | ﹤0.01% |
+400,000
| New | +$1.96M |
|
896
Eastern Bankshares
EBC
$3.4B
| $1.84M | ﹤0.01% |
90,493
-62,520
| -41% | -$1.27M |
|
897
Leggett & Platt
LEG
$1.32B
| $1.82M | ﹤0.01% |
+40,600
| New | +$1.82M |
|
898
DocGo
DCGO
$155M
| $1.82M | ﹤0.01% |
182,286
-482,176
| -73% | -$4.8M |
|
|
CAS
899
DELISTED
Cascade Acquisition Corp.
CAS
| $1.73M | ﹤0.01% |
173,050
| – | – |
|
|
RETA
900
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $1.71M | ﹤0.01% |
+17,000
| New | +$1.71M |
|